There were 438 press releases posted in the last 24 hours and 394,063 in the last 365 days.
MASSACHUSETTS — BOSTON, MA – March 16, 2023 – Massachusetts had 35,214 initial claims (IC) for regular Unemployment Insurance (UI) during the month of February, a decline of 1,623 from the previous month. Most initial claims this month were seen in …
WHAT: On Tuesday, March 21, 2023, the Trial Court will honor nine women as part of the court’s third annual Women’s History Month celebration, which will be held at Chelsea High School. This year’s theme is “Celebrating Women Who Tell Our Stories”. The …
Quincy, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Breezeline, the nation’s eighth-largest cable operator, has launched the next generation of TV, “Breezeline Stream TV,” in its Pennsylvania service areas, making it easier than ever for customers to view …
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Credit Suisse Group AG ADR (NYSE: CS) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn …
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the KeyBanc Capital Markets Life …
BURLINGTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Aware, Inc. (NASDAQ: AWRE) today announced a new partnership with Anyline, a global leader in mobile data capture and data insights, to integrate Knomi®, Aware’s industry-leading mobile biometric …
HINGHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which is rapidly scaling up its internal capabilities with globally renowned members joining its Scientific Advisory Board (SAB), today announced that Professor Mark W …
--Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 gene promotes resistance to immune checkpoint blockade in melanoma-- --Study provides valuable insights into the power of understanding the biology of CTCs to elucidate …
BURLINGTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today introduced its next-generation, AI-powered biometrics engine in Cerence Assistant, providing enhanced personalization and security …
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological …
DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response ( …
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster …
MARBLEHEAD, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- The Warrior Protection and Readiness Coalition (WPRC) announced that Senator Jerry Moran, and Congressman Chris Pappas (NH-01), have been awarded the 2023 WPRC Sentinel Award for their legislative …
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory …
CANTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the largest integrated commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported financial results for the fourth quarter and fiscal year …
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing Disclosure of initial data from Phase 1 arm of study expected in second half of 2023 MRT-2359 received Fast Track designation from FDA for treatment of patients …
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax …
WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to …
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing …
WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on …
